Biogen Idec Shifts Gears On Tysabri Relaunch
“Phase II” will focus on efficacy and broadening use of the multiple sclerosis therapy, CEO Mullen tells investors.
“Phase II” will focus on efficacy and broadening use of the multiple sclerosis therapy, CEO Mullen tells investors.